Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL96511 | 0.95 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL96930 | 0.92 | — | — | |
| SCHEMBL12442019 | 0.88 | ALDH1A1 (0.38) | ALDH1A1DPP4DPP7 | |
| SCHEMBL15680819 | 0.87 | ALDH1A1 (0.32) | ALDH1A1DPP4DPP7 | |
| SCHEMBL14997481 | 0.87 | — | — | |
| SCHEMBL96763 | 0.84 | — | — | |
| SCHEMBL19263932 | 0.84 | ALDH1A1 (0.37) | ALDH1A1DPP4DPP7 | |
| SCHEMBL28024899 | 0.82 | — | — | |
| SCHEMBL96773 | 0.81 | ALDH1A1 (0.39) | ALDH1A1DPP4 | |
| SCHEMBL16512808 | 0.81 | ALDH1A1 (0.39) | ALDH1A1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3150590-B1 | S1P MODULATING AGENTS | BIOGEN MA INC (US) | 2019-10-16 | — | — | EP | disclosed |
| EP-3150590-A1 | S1P MODULATING AGENTS | Biogen MA Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| WO-2012109108-A1 | S1P MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2012-08-16 | — | — | WO | disclosed |
| US-20120059008-A1 | DIALKYLAMINO ALKYL ESTERS OF PIVAGABINE AS MEDICAMENTS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | CENERX BIOPHARMA, INC. (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059008-A1 | DIALKYLAMINO ALKYL ESTERS OF PIVAGABINE AS MEDICAMENTS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | PMP22, CNR2, COQ8A | ALDH1A1 2193/4885DPP4 2835/4885DPP7 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.